Product Images Rivastigmine Transdermal System
View Photos of Packaging, Labels & Appearance
- Label - lbl721621610
- Chemical Structure - rivastigmine 01
- Figure 1 - rivastigmine 02
- Figure 2 - rivastigmine 03
- Figure 3 - rivastigmine 04
- Figure 4 - rivastigmine 05
- Figure 5 - rivastigmine 06
- Figure 6 - rivastigmine 07
- Figure 7 - rivastigmine 08
- Figure 8 - rivastigmine 09
- Figure A - rivastigmine 10
- Figure B - rivastigmine 11
- Figure C - rivastigmine 12
- Figure D - rivastigmine 13
- Figure E - rivastigmine 14
- Figure F - rivastigmine 15
- Figure G - rivastigmine 16
- Figure H - rivastigmine 17
Product Label Images
The following 18 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 72162-1610 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl721621610
This is a description of a transdermal system for administering rivastigmine, a medication used to treat symptoms of dementia. Each patch contains 27 mg of rivastigmine base with a release rate of 13.3 mg over 24 hours. The patches should be stored at room temperature and kept out of reach of children. It is recommended to apply the patch immediately after removing it from the pouch and not to store it unpouched. Instructions on proper usage and disposal can be found by scanning the QR code on the package insert.*
Chemical Structure - rivastigmine 01
Figure 1 - rivastigmine 02
Figure 2 - rivastigmine 03
Figure 3 - rivastigmine 04
This text seems to provide information about the change in ADAS-Cog rating from baseline during treatment with two different interventions: one involving capsules of 6 mg BID, and the other involving placebo. The data likely shows the least square means, as well as the standard error of the mean (SEM) at different time points, such as at 16 weeks. It also suggests that clinical improvement and decline are being evaluated.*
Figure 4 - rivastigmine 05
Figure 5 - rivastigmine 06
This text shows numeric data related to clinical improvement and decline over 52 weeks of treatment with Fivastomine and Tranadermal System. The study measures ADCS-IADL change from baseline using LS means SEM. The dosages used are 3.3 mg/24hr and 9.5 mg/24hr.*
Figure 6 - rivastigmine 07
This text provides information on a clinical study involving the ADAS-Cog scale and the assessment of cognitive decline over 48 weeks of treatment. The LS means and SEM are used to measure clinical improvement in the study.*
Figure 7 - rivastigmine 08
Figure 8 - rivastigmine 09
The text provides data regarding the LS mean change and standard error (STE) for a clinical study comparing two different treatment options over the course of several weeks. The study involves the use of Rivastigmine Transdermal Systems in two different sizes (15cm and 5cm) to assess improvement or decline. The results show significant differences in improvement between the two systems, with p-values provided for statistical significance. The study spanned up to 16 weeks of treatment.*
Figure A - rivastigmine 10
This text mentions a pouch containing Rivastigmine Transdermal System along with protective liners. It seems to be related to a medical product.*
Figure B - rivastigmine 11
This text provides a list of body parts where something can be evaluated or located. It includes the left or right upper arm, side of the chest, upper back, and lower back. This information may be used for medical assessments, physical exams, or injury documentation.*
Figure C - rivastigmine 12
Figure D - rivastigmine 13
This text mentions protective liners and a sticky surface of a patch possibly indicating the use of protective liners for adhesive patches. These protective liners are likely to serve as a barrier to protect the sticky surface until ready for use.*
Figure E - rivastigmine 14
Figure F - rivastigmine 15
Figure G - rivastigmine 16
Figure H - rivastigmine 17
This text provides instructions on how to dispose of a slide folded patch by placing it in the trash. It also mentions folding the sticky sides together into an empty pouch and keeping it away from children and pets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
